Yuanda Pharmaceutical's innovative ophthalmology products ar...
Yuanda Pharmaceutical's innovative ophthalmology products are expected to fill the demand in the hormonal ophthalmic formulation market. No new products have been launched in this market in the past ten years. Clinical trials of GPN00833 have verified its safety and efficacy, so it is expected to meet the demand for safe and potent hormone eye drops. As the ophthalmology market space and surgery volume grow, the market for hormonal ophthalmic preparations will expand.
Continuously promoting the innovative product development process, Yuanda Pharmaceutical (00512) GPN00833 completed the first phase III clinical administration of the first patient, which is expected to fill the domestic market demand for hormonal ophthalmic preparations
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment